和誉-B(02256)今日盘中股价大幅下挫6.14%，引发市场关注。
消息面上，公司近期发布了其核心产品贝捷迈®(盐酸匹米替尼胶囊，ABSK021)全球III期MANEUVER研究的积极结果，该结果已于国际顶级医学期刊《柳叶刀》正式发表，标志着该创新疗法获得了重要的国际学术认可。然而，市场似乎对此利好采取了“卖出事实”的反应。
分析认为，尽管该研究数据优异，显示药物在治疗腱鞘巨细胞瘤方面具有显著疗效和良好安全性，且其新药上市申请已获美国FDA受理，但在重大利好消息正式公布后，部分投资者选择获利了结，导致了股价的短期回调。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.